Post Kidney Transplant Nocturnal Hypertension Prevalence and Management Study

• Status: Withdrawn
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Hypertension (HTN) affects up to 75% of kidney transplant recipients and is associated with premature death. Nocturnal HTN is a common complication of ongoing essential HTN or a secondary cause of HTN. Both the non dipping of systolic blood pressure (SBP) at night time and the reverse dipping is associated with increased target organ damage and adverse cardiovascular outcomes and possibly allograft survival. Treatment of Nocturnal HTN is critical. Chronotherapy has been shown to be effective in halting progression in patients with diabetic nephropathy and chronic kidney disease. There is not enough data on prevalence and management of nocturnal HTN in transplant patients, which is the object of this study.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Northwell Health

Criteria

Inclusion Criteria:

1. Renal transplant more than 1 year ago and not on dialysis.

2. Age between 18 years to 70 years.

3. Known history of HTN on one or more anti-hypertensive medication.

4. Stable anti-hypertensive regimen for past 2 months

5. One of the anti-hypertensive regimen must include an ACE inhibitor, or an angiotensin receptor blocker, calcium channel blocker, alpha or beta blocker.

6. Stable immunosuppressive regimen with no dose changes in past 3 months.

7. No hospitalizations for previous 2 months

Exclusion Criteria:

1. Inability to consent

2. History of falls

3. Presence of AVF or AVG in both the arms

4. Inability to follow up in renal transplant clinic.

5. History of Atrial fibrillation.

6. Pregnant Women

7. Parkinson's Disease

8. Severe orthostatic Hypotension

9. Severe autonomic dysfunction

10. History of other transplanted organs